WVE WAVE Life Sciences

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 9, 2023, to review the company’s third quarter 2023 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: .

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: . Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit  and follow Wave on X (formerly Twitter) .

Investor Contact:

Kate Rausch

617-949-4827





Media Contact:

Alicia Suter

617-949-4817



EN
03/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

 PRESS RELEASE

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Li...

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the ...

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

 PRESS RELEASE

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results...

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events”...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch